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Ceramide is a well-characterized sphingolipid metabolite and second messenger that participates in numerous biological processes. In addition
to serving as a precursor to complex sphingolipids, ceramide is a potent signaling molecule capable of regulating vital cellular functions. Perhaps
its major role in signal transduction is to induce cell cycle arrest, and promote apoptosis. In contrast, little is known about the metabolic or
signaling pathways that are regulated by the phosphorylated form of ceramide. It was first demonstrated that ceramide-1-phosphate (C1P) had
mitogenic properties, and more recently it has been described as potent inhibitor of apoptosis and inducer of cell survival. C1P and ceramide are
antagonistic molecules that can be interconverted in cells by kinase and phosphatase activities. An appropriate balance between the levels of these
two metabolites seems to be crucial for cell and tissue homeostasis. Switching this balance towards accumulation of one or the other may result in
metabolic dysfunction, or disease. Therefore, the activity of the enzymes that are involved in C1P and ceramide metabolism must be efficiently
coordinated to ensure normal cell functioning.
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Tissue homeostasis in higher organisms is determined by a
network of complex processes that are tightly regulated. These
include systems to balance cell proliferation and cell death to
ensure proper development of the organism. Any alteration of
this balance can potentially lead to illnesses, including auto-
immune diseases, neural degeneration, cardiovascular disease,
or cancer [1–3]. Therefore, identification of effector molecules
that are involved in the regulation of cell proliferation and death
is crucial for developing therapeutical strategies for prevention
or treatment of disease.
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of cell activation with a wide spectrum of activity to control cell
growth and death, and signal transduction processes. For example,
ceramides are known to be potent inhibitors of cell growth and
efficient inducers of apoptosis [4–17] in most cell types. In
neurons, however, the situation is controversial as ceramides can
promote both apoptosis or cell survival [18–22]. Ceramides are
involved in the regulation of cell proliferation, differentiation,
apoptosis, or inflammatory responses [11,14,15,23–28], radiation
and chemotherapy effects on tumors, bacterial and viral infections,
heat or UVA injury, and ischemia–reperfusion injury (Reviewed
by Gulbins and Kolesnick [29]). In addition, ceramides have been
associated with insulin resistance through activation of protein
phosphatase 2A and the subsequent dephosphorylation and
inactivation of protein kinase B (PKB) [30–32]. By contrast,
sphingosylphosphorylcholine [33], sphingosine-1-phosphate
(S1P) [8,34–37], and ceramide-1-phosphate (C1P) [27,38–40]
are potent stimulators of cell proliferation. Ceramides can be
generated by de novo synthesis, or can be produced by the action
of different sphingomyelinase (SMase) enzymes (Fig. 1). For
details on SMase activities, enzymology, and compartmentaliza-
tion, see [12,41,42]. Cellular ceramides typically have long N-
acyl chains ranging from 16 to 26 carbons in length [7,43,44], and
some times longer in tissues such as skin. Many studies have used
a short-chain analog (N-acetylsphingosine, or C2-ceramide) in
experiments with cells in culture because it is more water soluble
than long-chain ceramides, and it has been presumed that this
compound did not occur in vivo. However, it was found that C2-
ceramide exists in rat liver cells [45]. The stimulation of
sphingomyelinase (SMase) activity was first demonstrated by
Kolesnick [9] in experiments using exogenous 1,2-dioctanoyl-
glycerol (a permeable analog of diacylglycerol) in GH3 pituitary
cells, and by Hannun and co-workers using 1,25-dihydroxyvita-
min D3 as agonist to stimulate HL-60 cells [23,46]. These actions
caused sphingomyelin (SM) hydrolysis and concomitantFig. 1. Formation of bioactive sphingolipids in mammalian cells. Ceramide can be
(SMase), or by de novo synthesis by the concerted action of serine palmitoyltransferas
complex sphingolipids. Ceramide can be metabolized to ceramide-1-phosphate by
phosphatase, or by lipid phosphate phosphatases (LPPs). Alternatively, ceramide
phosphorylated to sphingosine-1-phosphate by sphingosine kinases. The reverse react
phosphatases. Sphingomyelin N-deacylase generates sphingosylphosphorylcholine.increases in ceramide levels. It was suggested that sphingolipid-
derived metabolites might function as second messengers
[11,14,15,23–26].
The mechanisms whereby ceramides exert their biological
actions include modulation of diverse signal transduction path-
ways and key regulatory enzyme activities such as specific serine/
threonine kinases [10,11,47,48], protein phosphatases [49–51],
protein kinase C-ζ [52], stress-activated protein kinases (SAPK)
also known as Jun nuclear kinases (JNKs) [53,54], the mitogen-
activated protein kinases p42/44 [35,48], phospholipase A2
[55,56], protein kinase B (PKB) [30–32,57,58], or phospholipase
D (PLD) [59–61].
Formation of ceramide is also relevant because it is the
precursor of important bioactive sphingolipids that can also
regulate cellular functions. For instance, stimulation of cerami-
dases results in generation of sphingosine (Fig. 1), which was
first described as inhibitor of protein kinase C (PKC) [13]. There
are numerous reports in the scientific literature showing that
PKC is inhibited by exogenous addition of sphingosine to cells
in culture. Of note, Merrill and co-workers demonstrated that
addition of the ceramide synthase inhibitor fumonisin to J774
macrophages to increase the levels of endogenous sphingoid
bases, also inhibited protein kinase C [62]. Sphingosine can
control the activity of other key enzymes involved in the reg-
ulation of metabolic or cell signaling pathways such as the Mg2+
dependent form of phosphatidate phosphohydrolase [63,64],
phospholipase D (PLD) [65], or diacylglycerol kinase (DAGK)
[66,67] in different cell types. Sphingosine, in turn, can be
phosphorylated by the action of sphingosine kinases to generate
S1P, which is a potent mitogenic agent and can also inhibit
apoptosis in many cell types [8,34–37,68]. More recently, our
group demonstrated that S1P stimulates cortisol [69] and al-
dosterone secretion [70] in cells of the zona fasciculata or zona
glomerulosa, respectively, of bovine adrenal glands. These novel
actions of S1P implicate it in the regulation of steroidogenesis.produced through degradation of sphingomyelin (SM) by sphingomyelinases
e and dihydroceramide synthase. It can also be generated through metabolism of
ceramide kinase. The reverse reaction is catalyzed by ceramide-1-phosphate
can be degraded by ceramidases to form sphingosine, which can, in turn, be
ion is catalyzed by sphingosine-1-phosphate phosphatases, or by lipid phosphate
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(C1P), which can be formed through direct phosphorylation of
ceramide by ceramide kinase (Fig. 1). There is increasing evi-
dence suggesting that C1P can regulate cell proliferation and
apoptosis (Reviewed in [27,40]), and Chalfant's group has
demonstrated that C1P is involved in inflammatory responses
(reviewed in [71,72]). In addition, C1P plays a key role in
phagocytosis [73,74]. The aim of the present article is to review
recent developments related to the control of cell activation by
C1P with special emphasis to the role of C1P as a novel regulator
of cell survival.
2. Ceramide kinase and C1P generation
The existence of C1P was first reported by Dressler and
Kolesnick in human leukemia (HL-60) cells [75]. These authors
found that C1P was synthesized from ceramide that were derived
from SM but not from glycosphingolipids, and suggested that a
specific pathway extended from SM to C1P [75]. Ceramide
kinase (CERK) was first identified in brain synaptic vesicles by
Bajjalieh and co-workers [76], and subsequently found in HL-60
cells by Kolesnick and Hemer [10]. This activity was confined to
the microsomal membrane fraction, and it phosphorylated
ceramide but not 1,2-diacylglycerol, in the presence of physiologic
calcium concentrations [10]. Interestingly, human CERK has been
recently reported to be highly dependent on Mg2+ ions, and much
less dependent onCa2+ [77]. HumanCERKwas recently cloned by
Sugiura and co-workers [78]. The protein sequence has 537 amino
acids with two protein sequence motifs, an N-terminus that en-
compasses a sequence motif known as a pleckstrin homology (PH)
domain (amino acids 32–121), and a C-terminal region containing
a Ca2+/calmodulin binding domain (amino acids 124–433). Using
site-directed mutagenesis, Kim and co-workers found that leucine
10 in the PH domain is essential for its catalytic activity [79]. Also,
the same group has reported recently that the interaction between
the PH domain of CERK and phosphatidylinositol 4,5-bispho-
sphate regulates the plasma membrane targeting and C1P levels
[80]. CERK also contains the five conserved sequence stretches
(C1–C5) that are specific for lipid kinases (Reviewed in [81]).
With regards to substrate specificity, it was reported that
phosphorylation of ceramide by CERK is stereospecific [82].
The latter report also showed that a minimum of a 12-carbon
acyl chain was required for normal CERK activity, whereas the
short-chain ceramide analogues C8-ceramide, C4-ceramide, or
C2-ceramide were poor substrates for CERK. It was concluded
that CERK phosphorylates only the naturally occurring D-ery-
thro-ceramides [82]. The importance of CERK in cell signaling
was highlighted using specific RNAi to downregulate this en-
zyme activity in A549 lung adenocarcinoma cells. This treat-
ment dramatically inhibited arachidonic acid release and PGE2
production in response to ATP, the calcium ionophore A23187
and interleukin 1-β [71,83].
Recently, a human ceramide kinase-like (CERKL) enzyme
was identified in retina [84], and subsequently cloned [85].
However, this enzyme was unable to phosphorylate ceramide, or
other related lipids, under conditions commonly used to measure
CERK activity, and therefore its role in cell biology is unclear.In a previous report, Hinkovska-Galcheva et al. [73] ob-
served that endogenous C1P can be generated during the pha-
gocytosis of antibody-coated erythrocytes in human neutrophils
that were primed with formylmethionylleucylphenylalanine,
and more recently, the same group has established that C1P is a
mediator of phagocytosis [74]. Rile et al. [86] reported that C1P
can be formed in neutrophils upon addition of exogenous cell-
permeable [3H]N-hexanoylsphingosine (C6-ceramide) to the
cells. Riboni and co-workers [87] demonstrated that C1P could
be generated in cerebellar granule cells both from SM-derived
ceramide and through the recycling of sphingosine produced by
ganglioside catabolism. C1P can be also generated by the action
of interleukin 1-β on A549 lung adenocarcinoma cells [83], and
plays an important role in inflammation [71,83,88–91]. We
found that C1P is present in normal bone marrow-derived
macrophages isolated from healthy mice [92], and that C1P
levels were substantially decreased in apoptotic macrophages.
This observation suggested that C1P may play an important role
in cell survival [40,92]. In addition, C1P could potentially be
formed by the action of SMase D, which occurs in the venom of
a variety of arthropodes including spiders of the gender
Loxosceles (the brown recluse spider L. reclusa, L. amazonica,
L. arizonica, L. intermedia, L. laeta), and also in the toxins of
some bacteria such as Corynebacterium pseudotuberculosis, or
Vibrio damsela [93]. Envenomation by Loxosceles reclusa re-
sults in dermonecrosis, erythrocyte hemolysis, platelet aggre-
gation or renal failure, and can occasionally lead to death [94].
However, SMase D has broad substrate specificity, therefore,
the toxic effects of SMaseD cannot be attributed only to the
formation of C1P. Although there is no evidence for an anal-
ogous activity in mammalian cells, the possibility has not been
exhaustively explored.
To date, there have been few estimates of the actual mass
amounts of C1P in cells, however, the basal amounts may be
surprisingly high. Recent analyses by Merrill and co-workers as
part of the LipidMAPS Consortium (www.lipidmaps.org) have
posted the amounts of SM, Cer and C1P in RAW 264.7 cells
(see link to the 12/05/05 Kdo2-lipid A time course, http://www.
lipidmaps.org/data/kdo2lipidatimecourse/index.php, and exam-
ine the time zero column) as 441, 25 and 108 pmol/μg DNA,
respectively, which is equivalent to 5310, 300 and 1300 pmol/
mg protein (A. Merrill, personal communication). Therefore,
the C1P amounts of RAW 264.7 are about one fourth that for
SM, and several fold higher than Cer. One might speculate that
this high level of antiapoptotic C1P in the RAW 264.7 macro-
phages might be related to the relatively high resistance of these
cells to enter apoptosis when they are incubated in the absence
of serum, in comparison to other cell types.
3. Degradation of C1P
The identification of C1P phosphatase in rat brain [95], and
hepatocytes [96], together with the existence of CERK suggested
that ceramide and C1P are interconvertible in cells. C1P phos-
phatase was enriched in brain synaptosomes and liver plasma
membrane fractions, and appeared to be distinct from the phos-
phatase that hydrolyzes phosphatidic acid (PA), PA
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ceramide by the action of a PA phosphohydrolase that is
specifically located in the plasma membrane of cells [97]. The
latter enzymebelongs to a family of at least threemammalian lipid
phosphate phosphatases (LPPs) [98]. LPPs have recently been
shown to regulate cell survival by controlling the levels of
intracellular PA and S1P pools [99], and also to regulate leukocyte
infiltration and airway inflammation [100]. Dephosphorylation of
C1Pmight be a way of terminating its regulatory effects, although
the resulting formation of ceramide could potentially be
detrimental for cells. In any case, controlling the levels of
ceramide, and C1P by the coordinated action of CERK and C1P
phosphatases, may be of crucial importance for the metabolic or
signaling pathways that are regulated by these two sphingolipids.
Another possibility for degradation of C1P might be its
deacylation to S1P, which is then cleaved to a fatty aldehyde and
ethanolamine phosphate [4]. However, no C1P deacylase has so
far been identified in mammalian cells.
4. C1P promotes cell survival
We first reported that C1P was bioactive because it stim-
ulated DNA synthesis and cell division in rat fibroblasts [38].
These studies were performed using synthetic short-chain C1Ps
(C2-C1P and C8-C1P) that were enzymically synthesized using
C2- and C8-ceramides as substrates and bacterial diacylglycerol
kinase (DAGK). Also, we observed that the short-chain C1Ps
could partially reverse the morphological changes that are
induced in rat fibroblasts after prolonged serum deprivation, a
condition that induces apoptosis in these cells, and that the
short-chain C1Ps decreased the detachment of serum-starved
cells from the culture dishes (reviewed in [27]). Like the short-
chain C1Ps, a mixture of natural (long-chain) C1P that was
obtained from bovine brain also was a potent stimulator of DNA
synthesis. This action was accompanied by an increase in the
levels of proliferating cell nuclear antigen [39], which is a
marker of active DNA synthesis [101]. There is also evidence
suggesting a possible role for C1P in stimulating cell proli-
feration or inhibiting apoptosis in birds, as the short-chain
analog C8-C1P increased the size of cultured chick otic vesicle
explants, and inhibited DNA fragmentation in the same explants
incubated in the absence of serum [102]. It should however be
noted that C8-ceramide has not been found in biological
systems, and is a poor substrate for CERK [82]; so, it is unlikely
that C8-C1P occurs in vivo, and therefore, the effects of C8-C1P
should be regarded as pharmacological in nature, as previously
suggested [38]. In addition, it should be borne in mind that
synthetic short-chain analogs of ceramide or ceramide phos-
phate may not always mimic the effects of the natural (long-
chain) counterparts. In fact, Ping and Barrett have shown that
whereas ceramides can induce cell death in sensory neurons,
short-chain ceramide analogs promote survival [18]. As well,
Olivera and co-workers demonstrated that treatment of cells
with exogenous sphingomyelinase, which generates natural
(long-chain) ceramides in the plasma membrane, antagonized
the mitogenic effect of the phorbol ester 12-O-tetradecanoyl-
phorbol 13-acetate, while short-chain ceramide analogs had noeffect [103]. Furthermore, Sot and co-workers have recently
shown important differences in the biophysical behavior of
short- versus long-chain ceramides suggesting that they may
also behave differently in biological systems [104]. Therefore,
care should be taken when interpreting results from experiments
using only synthetic short-chain analogs.
The metabolic or signaling pathways that are regulated by
C1P are not well characterized, but unlike other related bio-
active phospholipids, including S1P, lyso-PA or PA, C1P does
not affect PLD, MAPK (ERK-1/2), adenylyl cyclase, Ca2+
mobilization, or the expression of the early genes c-fos or c-myc
in rat or mouse fibroblasts [38,39]. However, induction of ERK
phosphorylation has been demonstrated in human osteoblastic
cells that were stimulated with short-chain C1P [105], and C2-
C1P- or C8-C1P-induced Ca
2+ mobilization has been shown to
occur in calf pulmonary artery endothelial (CAPE) cells [106],
thyroid FRTL-5 [107], or Jurkat T-cells [108]. In the latter
report, Colina and co-workers showed that Ca2+ mobilization
by C8-C1P was dependent upon inositol (1,4,5)-trisphosphate
accumulation. By contrast, the short-chain C1Ps did not induce
Ca2+ mobilization in fibroblasts [38,39] or neutrophils [86], and
long-chain C16-C1P failed to alter intracellular Ca
2+ concentra-
tions in lung adenocarcinoma A549 cells [88]. Whether or not
natural C1P is able to affect Ca2+ homeostasis in any cell type
still remains to be determined.
We previously demonstrated that natural C1P blocked cell
death in bone marrow-derived macrophages that were incubated
in the absence of macrophage-colony stimulating factor (M-
CSF) [92], a condition known to induce apoptosis in these cells,
[109,110]. We found that C1P blocked both DNA fragmentation
and the stimulation of the caspase-9/caspase-3 pathway, thereby
suggesting that the prosurvival effect of C1P was due to in-
hibition of apoptosis [92]. A relevant finding was that apoptotic
macrophages had enhanced acid SMase activity and high levels
of ceramides compared to healthy cells [110,111]. Investigation
into the mechanism by which C1P exerts its antiapoptotic ef-
fects demonstrated complete inhibition of acid SMase and ce-
ramide accumulation by C1P in intact macrophages [92]. A key
observation in that study was that C1P blocked the activity of
acid SMase in cell homogenates suggesting that inhibition of
this enzyme occurs by direct physical interaction with C1P. It
was concluded that C1P is a natural and selective inhibitor of
acid SMase, and that inhibition of this enzyme activity is a
major mechanism whereby C1P promotes cell survival [92].
Also, this observation suggests that inhibition of acid SMase by
C1P is not mediated through receptor interaction. Acid SMase
was also inhibited by S1P in intact macrophages [111], but
unlike C1P the inhibitory effect of S1P did not involve direct
interaction with the enzyme. Also of interest, activation of acid
SMase plays an important role in pulmonary infections as it
facilitates internalization of bacteria into lung epithelial cells
[29]. Therefore, inhibition of acid SMase by C1P could be
important to reduce or prevent infection of mammalian cells.
The physiological relevance of the prosurvival effect of C1P
is underscored by the demonstration that intracellular levels of
C1P are substantially decreased in apoptotic macrophages. It
was hypothesized that the decrease in C1P concentration could
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triggering ceramide generation an apoptotic cell death [92].
A major mechanism whereby growth factors promote cell
survival is the activation of phosphatidylinositol 3-kinase (PI3-
K), which can lead to activation of the transcription factor NF-
κB, and expression of antiapoptotic genes. Using two different
experimental approaches, it was first demonstrated that PI3-K is
a target of C1P in bone marrow-derived macrophages [112].
PI3-K activation was demonstrated by immunoprecipitation of
the enzyme from whole cell lysates and assayed in vitro using
32P-phosphatidylinositol. In addition, an in vivo approach pro-
vided evidence of phosphatidylinositol (3,4,5)-trisphosphate
(PIP3) formation in intact cells that were prelabeled with 32P-
orthophosphate [112]. PIP3 is a major product of PI3-K activity,
and has recently been shown to directly inhibit acid SMase
[113]. Therefore, PI3-K activation may potentiate the inhibitory
effect of C1P on acid SMase through generation of PIP3 (Fig. 2).
Whether C1P and PIP3 bind to the same or different domains of
acid SMase remains to be elucidated.
C1P stimulated the phosphorylation of protein kinase B (PKB),
which is a target of kinases from different signaling pathways
including PI3-K [114,115], cAMP or cAMP-dependent protein
kinase (PKA) [116,117], and PKC-ζ [118]. C1P-induced
phosphorylation of PKB was sensitive to inhibition by wortman-
nin or LY294002, which are inhibitors of PI3-K activity. These two
inhibitors also completely blocked the prosurvival effect of C1P in
bone marrow-derived macrophages indicating that PKB is
downstream of PI3-K in this system, and important for the
antiapoptotic effect of C1P [112]. It was also reported that syn-
thetic C8-C1P induced phosphorylation of PKB in chick otic
vesicle explants [119]; however, it is unclear in that study whether
PKB is downstream of PKA, PKC, PI3-K or any other pathway
that may be involved in PKB phosphorylation in birds. Another
relevant finding was that C1P caused IkB phosphorylation and
stimulation of the DNA binding activity of NF-κB in primaryFig. 2. Working model for the promotion of cell survival and stimulation of cell
growth by Ceramide-1-phosphate. C1P prevents apoptosis by at least two primary
mechanisms: (1) by inhibition of A-SMase through direct interaction with the
enzyme, and the production of PIP3 ( the product of PI3-K), and 2) by activating the
PI3-K/PKB//NF-κBpathway leading to upregulation of antiapoptotic Bcl-XL. C1P
causes ERK1/2 activation to stimulate cell proliferation.cultures of mouse macrophages [112]. Of note, C1P upregulated
the expression of antiapoptotic Bcl-XL, which is a downstream
target of NF-κB (Fig. 2). The latter results provided the first
evidence for a novel biological role of natural C1P in the regulation
of cell survival by the PI3-K/PKB/NF-κB pathway in mammalian
cells [112].
As mentioned above, C1P can be metabolized to ceramide by
phosphatase activity, and then further converted to sphingosine
and S1P by ceramidases and sphingosine kinases, respectively.
Therefore, it could be speculated that the effects of C1P might be
mediated through C1P-derived metabolites. However, we pre-
viously demonstrated that ceramides and C1P are antagonistic
signals, and that C1P is unable to mimic many of the effects of
sphingosine or S1P (i.e., PLD activation, adenylyl cyclase inhi-
bition, or Ca2+ mobilization) [27,38,39,60,120]. Also, ceramides
can decrease the expression ofBcl-XL [71], whereas C1Pcauses its
up-regulation [112]. Finally, no ceramidases capable of converting
C1P to S1P have so far been identified, and S1P and C1P inhibit
acid SMase by different mechanisms [92,111]. Therefore, it can be
concluded that C1P acts on its own right to regulate cell functions.
It is obvious from the above observations that the activity of
the enzymes involved in ceramide and C1P metabolism must be
strictly regulated so that cells can keep appropriate levels of pro-
versus anti-apoptotic metabolites. Any alteration in the balance
between ceramides and C1P could potentially result in severe
disease, or might be fatal for cells. Increasing our knowledge on
the mechanisms that control ceramide and C1P levels may
facilitate the ability to develop new molecular strategies for coun-
teracting metabolic disorders.
5. Concluding remarks
The importance of C1P as regulator of cell survival is under-
scored by its ability to inhibit acid SMase and stimulate PI3-K.
Activation of PI3-K generates PIP3, which can also inhibit acid
SMase. This would reinforce the inhibitory effect of C1P on this
enzyme activity to prevent ceramide production, and block apop-
tosis. Also, ceramides are known no inhibit PKB, downstream of
PI3-K; so low levels of ceramidemight facilitate signaling through
the PI3-K pathway. Stimulation of PI3-K leads to activation of the
transcription factor NF-κB and the subsequent upregulation of
antiapoptotic Bcl-XL. Therefore, these actions of C1P result in
inhibition of cell death and promotion of cell survival. Further
work will help to identify new effectors of C1P and will lead to a
better understanding of the physiologic role of this intriguing
phosphosphingolipid in regulating cell homeostasis.
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